Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT
Wolfgang Miesbach/LinkedIn
Feb 17, 2026, 15:38

Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn, about a recent article by Jing Jing Wang et al, published in The New England Journal of Medicine։

”How a single mutation can flip a normal anti‑adenovirus response into a rare autoimmune clotting syndrome.

New NEJM paper on VITT after adenoviral COVID‑19 vaccines:

Genetics + somatic ‘hit’

Using antibody proteomics and germline sequencing in 100 VITT patients, the authors show that essentially all pathogenic anti‑PF4 antibodies come from B cells with the light‑chain allele IGLV3‑21*02/*03 and a stereotyped mutation at position 31 (lysine → glutamic acid, K31E) in the light‑chain CDR1. This charge flip, together with acidic motifs in LCDR2 (DDSD) and HCDR3 (ED), creates a strongly negatively charged paratope that binds tightly to positively charged PF4.

The adenoviral trigger

They identify molecular mimicry between PF4 and a highly basic epitope on adenoviral core protein VII (pVII). Only pVII‑purified antibodies carried the “VITT fingerprint”, and recombinant VITT antibodies bound both PF4 and this pVII peptide. When K31E was back‑mutated to germline K31, binding shifted back to pVII, PF4 binding dropped, and thrombosis in a human PF4/FcγRIIa mouse model was almost abolished.

Mechanistic model and implications

In IGLV3‑21*02/*03 carriers, prior adenovirus exposure seeds anti‑pVII memory B cells; on re‑exposure (ChAdOx1‑S, Ad26.COV2.S, or natural infection), rare clones acquire K31E, switch specificity from pVII to PF4, expand mono/oligoclonally, and produce high‑avidity anti‑PF4 IgG that form platelet‑activating PF4–IgG immune complexes.

This nicely explains: rapid ‘secondary’ onset (from day 5), stereotyped antibodies, and restriction to adenoviral vectors.

For future adenoviral platforms: engineer or replace pVII to remove this mimicking epitope, preserving vector function while further reducing an already extremely rare VITT risk — and providing a roadmap for dissecting other boosted autoimmune complications.”

Title: Adenoviral Inciting Antigen and Somatic Hypermutation in VITT

Authors: Jing Jing Wang, Linda Schönborn, Theodore E. Warkentin, Luisa Müller, Thomas Thiele, Lena Ulm, Uwe Völker, Andreas Greinacher

Read the Full Article on The New England Journal of Medicine․

Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT

Find more posts  featuring Wolfgang Miesbach on Hemostasis Today.

Andreas Greinacher bleeding disorders Covid-19 Health Hemostasis Hemostasis News Hemostasis Today Jing Jing Wang Lena Ulm Linda Schönborn Luisa Müller Medicine The New England Journal of Medicine Theodore E. Warkentin Thomas Thiele thrombosis Uwe Völker VITT Wolfgang Miesbach
NewsFeed